Valproate release from polycaprolactone implants prepared by 3D-bioplotting

Pharmazie

Volumn 66, Issue 7, 2011, Pages 511-516

  Kammerer, M ^a   Fabritius, M ^a   Carvalho, C ^a   Mulhaupt R ^a   Feuerstein, T J ^a   Trittler, R ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCAPROLACTONE; VALPROIC ACID; ANTICONVULSIVE AGENT; BIOMATERIAL; EXCIPIENT; POLYESTER;

ARTICLE; BIOCOMPATIBILITY; BIOTECHNOLOGICAL PROCEDURES; DRUG RELEASE; EPILEPTOGENESIS; FRACTIONATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMPLANT; LIMIT OF QUANTITATION; THREE DIMENSIONAL BIOPLOTTING TECHNOLOGY; TISSUE ENGINEERING; CALIBRATION; CHEMISTRY; DRUG IMPLANT; HYDROGEL; REPRODUCIBILITY; SOLUBILITY; STANDARD; THREE DIMENSIONAL IMAGING;

ANTICONVULSANTS; BIOCOMPATIBLE MATERIALS; CALIBRATION; DRUG IMPLANTS; EXCIPIENTS; HYDROGELS; IMAGING, THREE-DIMENSIONAL; POLYESTERS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLUBILITY; VALPROIC ACID;

EID: 80051922685     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0882     Document Type: Article

References (34)

1. Al-Ahmad A, Wiedmann-Al-Ahmad M, Carvalho C, Lang M, Follo M, Braun G, Wittmer A, Mülhaupt R, Hellwig E (2008) Bacterial and Candida albicans adhesion on rapid prototyping-produced 3D-scaffolds manufactured as bone replacement materials. J Biomed Mater Res A 87: 933-943.
2. Altman DG (1991) Statistics in medical journals: developments in the 1980s. Stat Med 10: 1897-1913.
3. Altman GH, Diaz F, Jakuba C, Calabro T, Horan RL, Chen J, Lu H, Richmond J, Kaplan DL (2003) Silk-based biomaterials. Biomaterials 24: 401-416. (Pubitemid 35291198)
4. Carcaboso AM, Chiappetta DA, Hocht C, Blake MG, Boccia MM, Baratti CM, Sosnik A (2008) In vitro/in vivo characterization of melt-molded gabapentin-loaded poly(epsilon-caprolactone) implants for sustained release in animal studies. Eur J Pharm Biopharm 70: 666-673.
5. Chang HI, Lau YC, Yan C, Coombes AG (2008) Controlled release of an antibiotic, gentamicin sulphate, from gravity spun polycaprolactone fibers. J Biomed Mater Res A 84: 230-237. (Pubitemid 350244264)
6. Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol doi: 10.1155/2010/479364.
7. Clayton-Smith J, Donnai D (1995) Fetal valproate syndrome. J Med Genet 32: 724-727.
8. Dreifuss FE, Langer DH, Moline KA, Maxwell JE (1989) Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 39: 201-217.
9. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB (1987) Valproic acid hepatic fatalities: a retrospective review. Neurology 37: 379-85. (Pubitemid 17031731)
10. Genton P, Semah F, Trinka E (2006) Valproic acid in epilepsy: pregnancy-related issues. Drug Saf 29: 1-21. (Pubitemid 43213892)
11. Gerstner T, Teich M, Bell N, Longin E, Dempfle CE, Brand J, König S (2006) Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 47: 1136-1143. (Pubitemid 44086748)
12. Goldberg D (1995) A review of the biodegradibility and utility of poly(caprolactone). J Environm Polym Degrad 3: 61-67.
13. Grosso S, Mostardini R, Piccini B, Balestri P (2009) Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother 43: 45-50.
14. Haberstroh K, Ritter K, Kuschnierz J, Bormann KH, Kaps C, Carvalho C, Mülhaupt R, Sittinger M, Gellrich NC (2010) Bone repair by cell-seeded 3D-bioplotted composite scaffolds made of collagen treated tricalciumphosphate or tricalciumphosphate-chitosan-collagen hydrogel or PLGA in ovine critical-sized calvarial defects. J Biomed Mater Res B Appl Biomater 93: 520-530.
15. Hutmacher DW (2000) Scaffolds in tissue engineering bone and cartilage. Biomaterials 21: 2529-2543.
16. Jagur-Grodzinski J (2006) Polymers for tissue engineering, medical devices, and regenerative medicine. Concise general review of recent studies. Polymers for advanced technologies 17: 395-498.
17. Jamora D, Lim SH, Pan A, Tan L, Tan EK (2007) Valproate-induced parkinsonism in epilepsy patients. Mov Disord 22: 130-233.
18. Kishore P, Rajani Kumar V, Satyanarayana V, Krishna DR (2003) HPLC determination of valproic acid in human serum. Pharmazie 58: 378-380. (Pubitemid 36733843)
19. Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342: 314-319. (Pubitemid 30075244)
20. Landers R, Hubner U, Schmelzeisen R, Mülhaupt R (2002a) Rapid prototyping of scaffolds derived from thermoreversible hydrogels and tailored for applications in tissue engineering. Biomaterials 23: 4437-4447. (Pubitemid 36151595)
21. Landers R, Pfister A, Hübner U, John H, Schmelzeisen R, Mülhaupt R (2002b) Fabrication of soft tissue engineering scaffolds by means of rapid prototyping techniques. J Mat Sci 37: 3107-3116. (Pubitemid 34950203)
22. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'Giano C (2007) ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 48 Suppl 5: 140-149. (Pubitemid 47512215)
23. Lendlein A (1999) Polymere als Implantatwerkstoffe. Chemie unserer Zeit 33: 279-295.
24. Löscher W (2007) Drug transporters in the epileptic brain. Epilepsia 48 Suppl 1: 8-13.
25. Mathiesen EB, Lindgren U, Reinholt FP, Sudmann E (1986) Wear of the acetabular socket. Comparison of polyacetal and polyethylene. Acta Orthop Scand 57: 193-196. (Pubitemid 16047961)
26. Michoulas A, Farrell K (2010) Medical management of Lennox-Gastaut syndrome. CNS Drugs 24: 363-374.
27. Neels HM, Sierens AC, Naelaerts K, Scharpe SL, Hatfield GM, Lambert WE (2004) Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 42: 1228-1255. (Pubitemid 39600327)
28. Olesen JB, Hansen PR, Erdal J, Abildstrom SZ,Weeke P, Fosbol EL, Poulsen HE, Gislason GH (2010) Antiepileptic drugs and risk of suicide: a nation-wide study. Pharmacoepidemiol Drug Saf 19: 518-524.
29. Ozkan S, Kalyon DM, Yu X, McKelvey CA, Lowinger M (2009) Multifunctional protein-encapsulated polycaprolactone scaffolds: fabrication and in vitro assessment for tissue engineering. Biomaterials 30: 4336-4347.
30. Pfister A, Landers R, Laib A, Hübner U, Schmelzeisen R, Mülhaupt R (2004) Biofunctional rapid prototyping for tissue-engineering applications: 3D bioplotting versus 3D printing. Journal of Polymer Science Part A: Polymer Chem 42: 624-638. (Pubitemid 38158961)
31. Serralta A, Barcia JA, Ortiz P, Duran C, Hernandez ME, Alos M (2006) Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model. Epilepsy Res 70: 15-26. (Pubitemid 43947512)
32. Tamargo RJ, Rossell LA, Kossoff EH, Tyler BM, Ewend MG, Aryanpur JJ (2002) The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res 48: 145-155. (Pubitemid 34252899)
33. Wang Y, Chang HI, Wertheim DF, Jones AS, Jackson C, Coombes AG (2007) Characterisation of the macroporosity of polycaprolactone-based biocomposites and release kinetics for drug delivery. Biomaterials 28: 4619-4627. (Pubitemid 47259167)
34. Wohlers T (2007) Wohlers Report 2007: Rapid Prototyping, Tooling & Manufacturing State of the Industry. Annual Worlwide Progress Report.